{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"}],"units":"Participants"}],"description":"RP2D was determined by MTD. MTD was defined as the highest dose at which 1 or fewer among 6 participants or \\<=33% experienced a DLT. DLT was defined as a TEAE or abnormal laboratory value related to study treatment (that is, assessed as unrelated to disease, intercurrent illness, or concomitant medications), including those TEAEs and abnormal laboratory values that resulted in a failure to meet the criteria for re-treatment. Available clinical data indicated that the MTD defined for the Q3W schedule was equal to the RP2D.","groups":[{"description":"Participants received mirvetuximab soravtansine IV infusion on Day 1 of every 21-day (Q3W) cycle. Dose escalation started at 0.15 mg/kg and proceeded through 7.0 mg/kg. Participants continued to receive mirvetuximab soravtansine (for clinical benefit) until unacceptable toxicity or withdrawal of consent, whichever came first, or until the sponsor terminated the study.","id":"OG000","title":"Dose Escalation: Schedule A (Mirvetuximab Soravtansine Q3W)"}],"paramType":"NUMBER","populationDescription":"Safety population included all participants who were enrolled and received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"Cycle 1 (21 days)","title":"Dose-Escalation Phase: Recommended Phase 2 Dose (RP2D) of Mirvetuximab Soravtansine","type":"PRIMARY","unitOfMeasure":"mg/kg"}